Released Oct 29, 2026, after the close
10-Q filed Nov 3, 2026, 34 days after period end · 0001193125-26-445326
On October 29, 2026, Stoke Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter end September 30, 2026.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $11.26M | $10.63M | $4.89M | $3.31M |
| Net Income | -$73.64M | -$38.35M | -$26.43M |
Stoke Therapeutics, Inc. · CIK 1623526 · Engraved from SEC EDGAR
| -$24.54M |
| EPS Diluted | -$1.08 | -$0.65 | -$0.47 | -$0.55 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Stoke Therapeutics reported $358.8 million in cash, cash equivalents and marketable securities as of September 30, 2026, which is expected to fund operations into early 2028.¶2
Revenue for the three months ended September 30, 2026 was $11.3 million, up from $10.6 million for the same period in 2025.¶3
Net loss for the three months ended September 30, 2026 was $73.6 million, or $1.08 per share, compared with a net loss of $38.3 million, or $0.65 per share, in 2025.¶4
Research and development expenses for the three months ended September 30, 2026 were $59.8 million, compared with $37.7 million for the same period in 2025.¶5
Enrollment of 162 patients in the Phase 3 EMPEROR study's primary analysis population was completed in June 2026, with a data readout anticipated in the third quarter of 2027.¶6